[Late-onset neutropenia following rituximab therapy as a treatment of diffuse large B-cell lymphoma: a single institution study].

BACKGROUND Late-onset neutropenia (LON) following rituximab therapy has been reported in recent years. However, its incidence has not been reported in Korea. The aim of this study is to investigate the incidence of LON after rituximab therapy in Korean patients with diffuse large B-cell lymphoma (DLBCL). METHODS Ninety-eight cases of DLBCL treated with rituximab between 2004 and 2008 were evaluated. We identified LON as defined by the neutrophil count of <1.5 × 10(9)/L without apparent cause after the recovery of neutrophil count following rituximab therapy. Bone marrow aspiration and biopsy specimens at the time of neutropenia were available for retrospective review in only 5 of the patients. RESULTS LON was observed in 15 (15.3%) of the 98 patients. In the bone marrow specimens of the 5 patients, promyelocytes were relatively increased and the maturation index of the granulopoiesis was 2:1-3:1, which reflects maturation arrest. CONCLUSIONS The incidence of LON following rituximab therapy was 15.3% in Korean patients with DLBCL. Although there are several hypotheses about the causative mechanisms of LON, we suggest that maturation arrest at the promyelocyte stage of granulopoiesis may be one of the mechanisms involved in the development of LON.

[1]  A. Chan,et al.  Late‐onset neutropenia following RCHOP chemotherapy in diffuse large B‐cell lymphoma , 2009, American journal of hematology.

[2]  J. Palmblad,et al.  Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis , 2008, Medical oncology.

[3]  X. Mariette,et al.  Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. , 2007, Haematologica.

[4]  Y. Kanda,et al.  A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  G. Rossi,et al.  Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments , 2006, Leukemia & lymphoma.

[6]  W. Wilson,et al.  B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. , 2005, Blood.

[7]  G. Salles,et al.  Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma , 2004, Bone Marrow Transplantation.

[8]  P. Solal-Céligny,et al.  Neutropenia in patients treated with rituximab. , 2003, The New England journal of medicine.

[9]  A. Grigg,et al.  Delayed‐onset neutropenia associated with rituximab therapy , 2003, British journal of haematology.

[10]  K. Stamatopoulos,et al.  Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases. , 2002, Leukemia research.

[11]  S. Advani,et al.  Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  H. Kuroda,et al.  Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab. , 2009, Internal medicine.